PT - JOURNAL ARTICLE AU - Owens, Katherine AU - Esmaeili-Wellman, Shadisadat AU - Schiffer, Joshua T. TI - Heterogeneous SARS-CoV-2 kinetics due to variable timing and intensity of immune responses AID - 10.1101/2023.08.20.23294350 DP - 2024 Jan 01 TA - medRxiv PG - 2023.08.20.23294350 4099 - http://medrxiv.org/content/early/2024/02/07/2023.08.20.23294350.short 4100 - http://medrxiv.org/content/early/2024/02/07/2023.08.20.23294350.full AB - The viral kinetics of documented SARS-CoV-2 infections exhibit a high degree of inter-individual variability. We identified six distinct viral shedding patterns, which differed according to peak viral load, duration, expansion rate and clearance rate, by clustering data from 768 infections in the National Basketball Association cohort. Omicron variant infections in previously vaccinated individuals generally led to lower cumulative shedding levels of SARS-CoV-2 than other scenarios. We then developed a mechanistic mathematical model that recapitulated 1510 observed viral trajectories, including viral rebound and cases of reinfection. Lower peak viral loads were explained by a more rapid and sustained transition of susceptible cells to a refractory state during infection, as well as an earlier and more potent late, cytolytic immune response. Our results suggest that viral elimination occurs more rapidly during omicron infection, following vaccination, and following re-infection due to enhanced innate and acquired immune responses. Because viral load has been linked with COVID-19 severity and transmission risk, our model provides a framework for understanding the wide range of observed SARS-CoV-2 infection outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Institutes of Health (NIH) grants R01AI169427 & R01AI121129Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data analyzed in this work was previously published by Hay et al. and is available on github at https://github.com/gradlab/SC2-kinetics-immune-history.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data analyzed in this work was previously published by Hay et al. and is available on github at https://github.com/gradlab/SC2-kinetics-immune-history. The code for generating all analysis and figures included in this manuscript is available at https://github.com/lacyk3/SARS-CoV-2Kinetics.